Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study
Phase 2
- Conditions
- COVID-19
- Interventions
- Drug: SSD8432 300mgDrug: SSD8432 750mgDrug: SSD8432Placebo
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT05373446
To Evaluate SSD8432/Ritonavir in Adults With COVID-19
Phase 2
- Conditions
- COVID-19
- Interventions
- Drug: SSD8432 placeboDrug: SSD8432 750mg
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 670
- Registration Number
- NCT05373433
To Evaluate SSD8432/ Ritonavir in Adults With COVID-19
Phase 1
Completed
- Conditions
- COVID-19 Patients
- Interventions
- Drug: SSD8432 dose 1/RitonavirDrug: SSD8432 dose 2/Ritonavir
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05369676
- Locations
- 🇨🇳
Shenzhen Third People's Hospital, Shenzhen, Guangdong, China
A Phase I Clinical Study of SSD8432 in Healthy Adult Subjects
Phase 1
- Conditions
- Healthy Participants
- Interventions
- Drug: SSD8432 dose 8~9Drug: SSD8432 dose 14 and RitonavirDrug: SSD8432 dose 13 and RitonavirDrug: SSD8432 dose 1~7 and RitonavirDrug: SSD8432 dose 10~12 and ritonavir
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT05339646
- Locations
- 🇨🇳
The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, China
Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 214
- Registration Number
- NCT05293964
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT05254665
- Locations
- 🇨🇳
The Forth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Shandong Cancer Hospital, Jinan, Shandong, China
🇨🇳Jinhua Municipal Hospital Medical Group, Jinhua, Zhejiang, China
The Tolerability, Safety, and PK Characteristics of SIM1910-09 in Healthy Chinese Volunteers
Phase 1
Completed
- Conditions
- Acute Ischemic StrokeCerebral Edema
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT05200728
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
Phase 2
Terminated
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT05148195
- Locations
- 🇨🇳
Sun Yat-sen University affiliated with the Sixth Hospital, Guangzhou, China
🇨🇳Shaw Hospital Affiliated to Medical College of Zhejiang Universit, Hangzhou, China
🇨🇳Beijing Cancer Hospital, Beijing, China
Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05071703
- Locations
- 🇨🇳
Hainan General Hospital, Haikou, Hainan, China
PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy
Phase 1
- Conditions
- Advanced or Metastatic NSCLC
- Interventions
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04942301
- Locations
- 🇨🇳
Lan Mu, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath